Dianthus initiated with a Buy at Clear Street

Clear Street analyst Bill Maughan initiated coverage of Dianthus (DNTH) with a Buy rating and $100 price target Dianthus is a biotech company primarily developing claseprubart for the treatment of complement-driven autoimmune diseases, the analyst tells investors in a research note. The firm believes claseprubart is a “best-in-class” complement inhibitor that is well positioned to improve on the standard of care in each of the three indications currently being tested in the clinic. It sees $1B-$2B of sales potential in each of these opportunities.